Systems Analysis of Arrestin Pathway Functions - Progress in Molecular Biology and Translational Science - page 445

4. Davies AO, Lefkowitz RJ. Agonist-promoted high affinity state of the beta-adrenergic
receptor in human neutrophils: modulation by corticosteroids. J Clin Endocrinol Metab .
1981;53:703- 708.
5. DeLean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-
specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.
J Biol Chem . 1980;255:7108- 7117.
6. Kenakin T. Drugs and receptors. An overview of the current state of knowledge. Drugs .
1990;40:666- 687.
7. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of
the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem .
1993;268:4625- 4636.
8. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-
occupancy model. III. Resurrecting efficacy. J Theor Biol . 1996;181:381- 397.
9. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-
dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-
directed trafficking of receptor stimulus. Mol Pharmacol . 1988;54:94- 104.
10. Sagan S, Chassaing G, Pradier L, Lavielle S. Tachykinin peptides affect differently the
second messenger pathways after binding to CHO-expressed human NK-1 receptors.
J Pharmacol Exp Ther . 1996;276:1039 - 1048.
11. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. Differential
desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 acti-
vation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem .
2004;279:23214 - 23222.
12. Maudsley S, Davidson L, Pawson AJ, Chan R, L´pez de Maturana R, Millar RP.
Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signal-
ing in peripheral reproductive tumor cells by activating a Galphai-coupling state of
the type I GnRH receptor. Cancer Res . 2004;64:7533 - 7544.
13. Caunt CJ, Finch AR, Sedgley KR, Oakley L, Luttrell LM, McArdle CA. Arrestin-
mediated ERK activation by gonadotropin-releasing hormone receptors: receptor-
specific activation mechanisms and compartmentalization. J Biol Chem . 2006;281:
2701- 2710.
14. Bockaert J, Dumuis A, Fagni L, Marin P. GPCR-GIP networks: a first step in the dis-
covery of new therapeutic drugs? Curr Opin Drug Discov Dev . 2004;7:649 - 657.
15. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the
impact of allosteric modulation and functional selectivity on new drug discovery.
Pharmacol Rev . 2010;62:265 - 304.
16. Martin B, Chadwick W, Yi T, et al. VENNTURE—a novel Venn diagram investi-
gational tool for multiple pharmacological dataset analysis. PLoS One . 2012;7:e36911.
17. Gesty-Palmer D, Luttrell LM. Refining efficacy: exploiting functional selectivity for
drug discovery. Adv Pharmacol . 2011;62:79 - 107.
18. Maudsley S, Patel SA, Park SS, Luttrell LM, Martin B. Functional signaling biases in
G protein-coupled receptors: game theory and receptor dynamics. Mini Rev Med Chem .
2012;12:831 - 840.
19. Wu WW, Wang G, Insel PA, et al. Discovery- and target-based protein quantification
using iTRAQ and pulsed Q collision induced dissociation (PQD). J Proteomics .
2012;75:2480- 2487.
20. Maudsley S, Chadwick W, Wang L, Zhou Y, Martin B, Park SS. Bioinformatic
approaches to metabolic pathways analysis. Methods Mol Biol . 2011;756:99 - 130.
21. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing
seven-transmembrane receptors. Nat Rev Drug Discov . 2012;9:373 - 386.
22. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S. Allosteric modulators of
G protein-coupled receptors: future therapeutics for complex physiological disorders.
J Pharmacol Exp Ther . 2009;331:340 - 348.